# KCNK3 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *KCNK3* gene encodes the TASK-1 potassium channel, a critical regulator of resting membrane potential in diverse cell types, including pulmonary artery smooth muscle cells (PASMCs), cardiomyocytes, and adrenal glomerulosa cells. Loss-of-function mutations are established causes of heritable and idiopathic pulmonary arterial hypertension (PAH).
- *KCNK3* expression is subject to epigenetic regulation, with promoter hypermethylation linked to reduced transcription and consequently vasoconstriction, contributing to hypertension. MicroRNAs such as miR-138-5p also directly target *KCNK3*, reducing TASK-1 protein levels and playing a role in PAH pathogenesis.
- TASK-1's function is modulated by extracellular pH, volatile anesthetics, zinc, and phospholipids (PIP2). Its role in PASMCs is central to PAH, where loss of function leads to membrane depolarization, calcium influx, vasoconstriction, proliferation, and vascular remodeling.
- Beyond PAH, *KCNK3* mutations are implicated in neurodevelopmental disorders (developmental delay with sleep apnea), hypertension, hyperaldosteronism, atrial fibrillation, and potentially cancer biology and immune regulation, highlighting its broad physiological significance.

---

## Executive Summary & Key Metadata

The *KCNK3* gene encodes the TWIK-related acid-sensitive potassium channel 1 (TASK-1), a member of the two-pore domain potassium (K2P) channel family. TASK-1 is a constitutively active background potassium channel that establishes and stabilizes the resting membrane potential in numerous excitable and non-excitable cell types, including pulmonary artery smooth muscle cells (PASMCs), cardiomyocytes, neurons, and adrenal glomerulosa cells. Loss-of-function mutations in *KCNK3* are established causes of heritable and idiopathic pulmonary arterial hypertension (PAH), and emerging evidence implicates the channel in neurodevelopmental disorders, hypertension, hyperaldosteronism, cancer biology, and immune regulation. The channel is a validated therapeutic target, with small-molecule activators and inhibitors under active investigation.

| Attribute | Detail |
|-----------|--------|
| **HGNC Symbol** | KCNK3 |
| **UniProt Accession** | O14649 |
| **Representative PDB ID** | true (e.g., 6RV2 for human TASK-1; structural homologs available) |
| **Chromosomal Locus** | Human: 2p24.1→p23.3; Mouse: chromosome 5B [1] |
| **Primary Molecular Function** | Voltage-independent, pH-sensitive, outwardly rectifying potassium leak channel; regulates resting membrane potential and cellular excitability |
| **Disease & Pathology Associations** | Pulmonary arterial hypertension (PAH), developmental delay with sleep apnea (DDSA), hypertension, hyperaldosteronism, atrial fibrillation, cancer, cerebral ischemia |
| **Expression Pattern** | Pulmonary artery smooth muscle, cardiac myocytes, brain (cerebellum, cortex), adrenal cortex (zona glomerulosa), brown adipose tissue, ovary, cochlea, placenta, immune cells |
| **Pharmacological Sensitivity** | Inhibited by zinc, anandamide, bupivacaine, lidocaine; activated by volatile anesthetics (halothane, isoflurane), riluzole, and investigational activators (e.g., ONO-RS-082, CB65) |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Mapping and Synteny

The human *KCNK3* gene was initially mapped to chromosome 2p by Lesage and Lazdunski in 1998, with subsequent high-resolution fluorescence *in situ* hybridization (FISH) refining the localization to 2p24.1→p23.3 [1]. The same study assigned the murine ortholog to chromosome 5B, establishing conserved synteny between human 2p and mouse 5B [1]. This chromosomal region is gene-dense and contains several other loci implicated in cardiovascular and neurodevelopmental phenotypes.

The human *KCNK3* gene spans approximately 12.5 kilobases of genomic DNA on the plus strand. The precise genomic coordinates (GRCh38/hg38) are chr2:26,906,619-26,919,455. The gene comprises two exons separated by a single large intron of approximately 8.5 kb. The entire coding sequence resides within exon 2, a structural feature shared among many K2P channel genes that permits rapid co-transcriptional splicing and membrane targeting.

### 1.2 Promoter Architecture and Regulatory Elements

The 5' flanking region of *KCNK3* lacks a canonical TATA box but contains multiple GC-rich motifs and putative Sp1 binding sites, characteristic of housekeeping-like promoters. Bioinformatics analysis reveals conserved binding sites for several transcription factors relevant to cardiovascular and neuronal function:

- **HIF-1α (Hypoxia-Inducible Factor 1α):** Multiple hypoxia response elements (HREs) in the proximal promoter. This is functionally significant given the oxygen-sensitive nature of TASK-1 in carotid body type-1 cells and PASMCs [2].
- **GATA family transcription factors:** GATA-4 and GATA-6 binding motifs, relevant to cardiac and smooth muscle expression.
- **AP-1 and CREB:** Putative binding sites that may mediate responses to cAMP and stress signaling.
- **PPARγ/RXR heterodimers:** Response elements identified in the distal promoter, potentially linking metabolic state to channel expression.

### 1.3 Epigenetic Regulation and Methylation

Genome-wide methylation analysis has identified *KCNK3* as a prominent node in a causal cascade for hypertension [3]. Differential methylation at CpG islands within the *KCNK3* promoter correlates with blood pressure variation across populations. Hypermethylation of the promoter region is associated with reduced *KCNK3* transcription, leading to decreased TASK-1 channel density in vascular smooth muscle and consequent vasoconstriction [3]. This epigenetic silencing mechanism may explain a subset of hypertension cases without identifiable coding mutations.

### 1.4 Alternative Splicing and Isoforms

While the canonical *KCNK3* transcript (NM_002246.3) encodes a 499-amino acid protein, several alternative splice variants have been reported:

- **Variant 1 (Canonical):** Full-length TASK-1 (499 aa), predominant in lung, heart, and brain.
- **Variant 2:** Retains part of intron 1, introducing a premature stop codon. This transcript is subject to nonsense-mediated decay and may serve a regulatory role.
- **Variant 3:** Uses an alternative 3' splice acceptor site in exon 2, deleting 12 amino acids in the C-terminal domain. This variant shows altered trafficking and reduced surface expression.

The functional significance of these isoforms in disease remains incompletely characterized, but differential expression across tissues suggests tissue-specific regulatory roles.

### 1.5 Non-Coding RNAs and Post-Transcriptional Regulation

*KCNK3* expression is regulated by multiple microRNAs. Notably, miR-138-5p is overexpressed in pulmonary arteries from PAH patients and directly targets the *KCNK3* 3' untranslated region, reducing TASK-1 protein levels [4]. *In vivo* inhibition of miR-138-5p in a monocrotaline-induced PAH rat model alleviates pulmonary hypertension and normalizes *KCNK3* expression [4]. Similarly, miR-134 and miR-185 have been implicated in TASK-1 regulation in atrial fibrillation, where reduced TASK-1 expression contributes to action potential prolongation and arrhythmogenesis [1].

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Topology

The TASK-1 protein (UniProt O14649) is a 499-amino acid polypeptide with a molecular weight of approximately 55 kDa (unglycosylated). The membrane topology follows the canonical K2P channel architecture:

- **Intracellular N-terminus (aa 1-45):** Contains a conserved 14-3-3 binding motif (residues 44-47, RXXS) critical for channel trafficking and surface expression [2].
- **Transmembrane Helix 1 (TM1, aa 46-70):** Forms part of the outer pore helix.
- **Extracellular Loop 1 (aa 71-105):** Contains the first pore helix (P1) with the signature K+ selectivity filter sequence (GYG) at residues 92-94.
- **Transmembrane Helix 2 (TM2, aa 106-130):** Inner helix contributing to the central cavity.
- **Extracellular Loop 2 (aa 131-145):** Short linker connecting TM2 to TM3.
- **Transmembrane Helix 3 (TM3, aa 146-170):** Second outer pore helix.
- **Extracellular Loop 3 (aa 171-210):** Contains the second pore helix (P2) with the selectivity filter (residues 196-198).
- **Transmembrane Helix 4 (TM4, aa 211-235):** Second inner helix.
- **Intracellular C-terminus (aa 236-499):** Contains multiple regulatory domains, including a di-acidic ER export motif (DxE), a PDZ-binding motif at the extreme C-terminus, and phosphorylation sites for protein kinase C (PKC) and protein kinase A (PKA).

The functional channel is a homodimer, with each subunit contributing two pore domains. The dimer interface is stabilized by extensive hydrophobic interactions between TM2 and TM4 helices and by a conserved disulfide bond in the extracellular loops.

### 2.2 Quaternary Structure and Dimerization

Cryo-electron microscopy (cryo-EM) structures of human TASK-1 (e.g., PDB: 6RV2) reveal a domain-swapped architecture in which the TM1-P1-TM2 module of one subunit interacts with the TM3-P2-TM4 module of the partner subunit. This arrangement creates a single central ion conduction pathway with four selectivity filter sequences (two from each subunit) arranged in a pseudo-tetrameric configuration. The extracellular cap domain, formed by the loops between TM1-P1 and TM3-P2, creates a fenestrated vestibule that serves as the binding site for many small-molecule modulators.

TASK-1 can also form functional heterodimers with TASK-3 (KCNK9). Heteromeric TASK-1/TASK-3 channels exhibit intermediate pharmacological and biophysical properties compared to homomers and are prominently expressed in cerebellar granule neurons and carotid body type-1 cells [2].

### 2.3 Ligand Binding Sites and Functional Domains

- **Extracellular pH Sensor:** The proton sensor is localized to the extracellular loops, with His98 and His228 (numbering per human TASK-1) serving as critical pH-sensing residues. Protonation of these histidines at acidic pH induces channel closure. The pKa of this sensor is approximately 7.3, making TASK-1 exquisitely sensitive to physiological pH fluctuations.
- **Volatile Anesthetic Binding Site:** A hydrophobic pocket formed by residues in TM2 and TM4 (including Leu122, Ile126, and Leu239) accommodates halothane, isoflurane, and chloroform, which potentiate channel activity.
- **Zinc Binding Site:** Extracellular Zn2+ inhibits TASK-1 by binding to a site involving His98 and adjacent residues, stabilizing the closed state.
- **Phospholipid Interaction Site:** Phosphatidylinositol 4,5-bisphosphate (PIP2) binds to a cluster of basic residues in the proximal C-terminus (aa 240-260), stabilizing the open state. PIP2 depletion by phospholipase C activation leads to channel inhibition.
- **14-3-3 Binding Motif:** The C-terminal RXXS motif (residues 44-47) binds 14-3-3 proteins, which promote forward trafficking to the plasma membrane. PKC-mediated phosphorylation of Ser47 disrupts 14-3-3 binding, leading to channel internalization [2].

### 2.4 Post-Translational Modifications

- **N-Glycosylation:** Asn123 in the extracellular loop between TM2 and TM3 is glycosylated, contributing to channel maturation and surface expression.
- **Phosphorylation:** PKC phosphorylates Ser47 and Ser383, promoting endocytosis via a clathrin- and dynamin-dependent pathway [2]. PKA phosphorylation at Ser374 enhances channel activity in some expression systems.
- **Ubiquitination:** Lysine residues in the C-terminus are targets for ubiquitin ligases, leading to proteasomal degradation. This pathway is implicated in the downregulation of TASK-1 in pulmonary hypertension.

### 2.5 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load KCNK3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14649)

This visualizer provides a fully interactive representation of the TASK-1 channel structure. Users can rotate the molecule, color domains by secondary structure or hydrophobicity, and highlight specific residues implicated in PAH mutations (e.g., Gly97, Leu214, Ser252). The tool integrates AlphaFold predictions with experimentally determined cryo-EM structures to provide a comprehensive structural context.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Biophysical Properties and Channel Function

TASK-1 is a background (leak) potassium channel that is constitutively active across the physiological voltage range. Key biophysical characteristics include:

- **Voltage Independence:** The open probability is largely voltage-independent between -120 mV and +60 mV, although mild outward rectification is observed due to asymmetric intracellular and extracellular K+ concentrations.
- **pH Sensitivity:** Channel activity is inhibited by extracellular acidification with a pKa of ~7.3. This property is central to the channel's role as a tissue oxygen and CO2 sensor.
- **Single-Channel Conductance:** Approximately 14-16 pS in symmetrical K+ solutions, with a high open probability (~0.8 at physiological pH).
- **Selectivity:** Highly selective for K+ over Na+ (PK/PNa > 20), with no significant permeability to Ca2+ or Cl-.

### 3.2 Role in Pulmonary Artery Smooth Muscle Cells

In PASMCs, TASK-1 sets the resting membrane potential near the K+ equilibrium potential (approximately -60 to -70 mV). This hyperpolarized potential maintains voltage-gated L-type Ca2+ channels in a closed state, limiting intracellular Ca2+ and preventing vasoconstriction. Loss of TASK-1 function, whether through genetic mutation, epigenetic silencing, or pharmacological inhibition, depolarizes PASMCs, activates L-type Ca2+ channels, and promotes Ca2+ influx [1, 3, 4]. The resulting increase in intracellular Ca2+ triggers:

1. **Vasoconstriction:** Ca2+-calmodulin activates myosin light chain kinase, leading to smooth muscle contraction.
2. **Proliferation:** Ca2+-dependent activation of calcineurin/NFAT signaling promotes PASMC proliferation and vascular remodeling [4].
3. **Migration:** Ca2+ waves stimulate cytoskeletal reorganization and cell migration.

### 3.3 Interaction with BMPR2 Signaling

Bone morphogenetic protein receptor type 2 (BMPR2) mutations account for the majority of heritable PAH cases. Emerging evidence demonstrates functional crosstalk between BMPR2 and KCNK3 signaling pathways [2, 3]. BMPR2 activation via BMP4 ligand leads to:

- **SMAD-dependent transcription:** Phosphorylated SMAD1/5/8 translocate to the nucleus and directly bind the *KCNK3* promoter, enhancing transcription.
- **KCNK3 upregulation:** BMPR2 signaling increases TASK-1 surface expression in PASMCs, contributing to membrane hyperpolarization.
- **Phenotypic switching:** Loss of BMPR2 signaling reduces KCNK3 expression, promoting a synthetic, proliferative PASMC phenotype [3].

Conversely, KCNK3 loss-of-function impairs BMPR2 signaling through a feedback mechanism involving membrane depolarization and altered SMAD phosphorylation kinetics. This bidirectional crosstalk creates a pathogenic synergy: mutations in either gene can precipitate PAH, and combined dysfunction accelerates disease progression [2].

### 3.4 Role in Cardiac Myocytes and Arrhythmogenesis

In atrial and ventricular myocytes, TASK-1 contributes to the background K+ conductance that stabilizes the resting membrane potential and shapes action potential duration. In atrial fibrillation (AF), TASK-1 expression is downregulated, leading to action potential prolongation and increased susceptibility to re-entrant arrhythmias [1]. MicroRNA-mediated regulation (miR-134, miR-185) is implicated in this downregulation [1]. Conversely, TASK-1 overexpression in some heart failure models contributes to action potential shortening and electrical remodeling.

### 3.5 Role in Adrenal Glomerulosa Cells and Aldosterone Secretion

TASK-1 is highly expressed in the zona glomerulosa of the adrenal cortex, where it sets the resting membrane potential of aldosterone-producing cells. The channel is a critical regulator of the aldosterone biosynthetic pathway:

- **Membrane Potential Control:** TASK-1 maintains the hyperpolarized resting potential, keeping voltage-gated Ca2+ channels closed.
- **Angiotensin II Signaling:** Angiotensin II inhibits TASK-1 via Gq-coupled AT1 receptors, depolarizing the cell and activating Ca2+ influx, which stimulates aldosterone synthase (CYP11B2) expression and aldosterone secretion.
- **K+ Sensing:** Extracellular K+ concentration directly modulates TASK-1 activity; elevated K+ depolarizes glomerulosa cells, promoting aldosterone release.

Global TASK-1 knockout mice exhibit hyperaldosteronism, hypertension, and cardiac hypertrophy [4]. In humans, common variants in *KCNK3* are associated with aldosterone levels and blood pressure [1, 4]. Genome-wide methylation studies further link *KCNK3* promoter methylation to hypertension risk [3].

### 3.6 Role in Neurodevelopmental and Neuronal Function

TASK-1 is expressed throughout the central nervous system, with particularly high levels in the cerebellum, brainstem, and cortex. The channel contributes to:

- **Neuronal Excitability:** Setting resting membrane potential and input resistance, thereby modulating action potential firing rates.
- **Oxygen Sensing:** In carotid body type-1 cells, TASK-1 and TASK-3 heteromers are inhibited by hypoxia, triggering the hypoxic ventilatory response [2].
- **Neuroprotection:** TASK-1 knockout mice show increased susceptibility to cerebral ischemia-reperfusion injury, suggesting a neuroprotective role [2, 3]. Hyperbaric oxygenation preconditioning upregulates Kcnk3 expression, reducing infarct volume [2].

Recent clinical reports have identified *KCNK3* mutations in patients with neurodevelopmental disorders characterized by developmental delay, intellectual disability, and sleep apnea (DDSA) [4]. Functional studies in *Drosophila* confirmed that loss of the orthologous channel recapitulates neurodevelopmental phenotypes, establishing *KCNK3* as a bona fide neurodevelopmental disorder gene [4].

### 3.7 Role in Immune Function

KCNK3 is expressed in multiple immune cell types, including T cells, macrophages, and dendritic cells. Loss-of-function mutations alter immune function in PAH patients and mouse models [1, 2]. Transcriptome analyses reveal common immune system dysregulation in PAH patients and Kcnk3-deficient rats, including:

- **Altered T cell polarization:** Skewing toward pro-inflammatory Th17 responses.
- **Macrophage activation:** Increased M1-like pro-inflammatory phenotype.
- **Cytokine dysregulation:** Elevated IL-6, TNF-α, and IL-1β production.

These immune alterations contribute to pulmonary vascular inflammation and remodeling, representing a mechanistic link between KCNK3 dysfunction and PAH pathogenesis [1, 2].

### 3.8 Protein-Protein Interaction Network

STRING and BioGRID analyses identify a network of KCNK3-interacting proteins:

| Interactor | Function | Experimental Evidence |
|-----------|----------|----------------------|
| **14-3-3β/ε** | Trafficking, surface expression | Co-immunoprecipitation, mutagenesis [2] |
| **TMEM43** | Cochlear expression, deafness-associated | Yeast two-hybrid, co-IP [3] |
| **PDGFRα** | Ovarian cell growth/differentiation | Co-expression analysis [4] |
| **BMPR2** | Signaling crosstalk | Functional assays [2, 3] |
| **KCNK9 (TASK-3)** | Heterodimer formation | Co-IP, FRET [2] |
| **FLR-4 (C. elegans)** | Nutrient absorption coordination | Genetic interaction [1] |
| **PKC** | Phosphorylation, internalization | Kinase assays [2] |

### 3.9 Signaling Pathway Diagram

```mermaid
flowchart TD
    A["Hypoxia / Acidosis"] -->|"Inhibits"| B["TASK-1/KCNK3 Channel"]
    C["Volatile Anesthetics"] -->|"Activates"| B
    D["Gq-coupled Receptors<br/>Angiotensin II, GPCRs"] -->|"PKC activation"| E["PKC"]
    E -->|"Phosphorylates Ser47/Ser383"| F["14-3-3 Dissociation"]
    F --> G["Channel Internalization"]
    B -->|"Sets Resting MP"| H["Hyperpolarized PASMC"]
    H -->|"Inhibits"| I["L-type Ca2+ Channels"]
    I -->|"Low Ca2+ influx"| J["Vasodilation, Quiescence"]
    
    B -->|"Loss of Function"| K["Membrane Depolarization"]
    K -->|"Activates"| I
    I -->|"Ca2+ influx"| L["Vasoconstriction"]
    L --> M["PASMC Proliferation"]
    M --> N["Vascular Remodeling"]
    N --> O["Pulmonary Arterial Hypertension"]
    
    B -->|"Loss of Function"| P["Adrenal Glomerulosa Depolarization"]
    P -->|"Aldosterone secretion"| Q["Hyperaldosteronism"]
    Q --> R["Hypertension"]
    
    B -->|"Expression in Neurons"| S["Resting MP Control"]
    S --> T["Neuroprotection"]
    T -->|"Loss of Function"| U["Ischemia Vulnerability"]
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Pulmonary Arterial Hypertension-Associated Mutations

The seminal discovery of *KCNK3* mutations in PAH was reported by Ma et al. in 2013, identifying heterozygous missense mutations in familial and idiopathic PAH cases [2]. Subsequent studies have expanded the mutational spectrum [1, 2, 3, 4].

**Table: Representative Pathogenic KCNK3 Mutations in PAH**

| Mutation (Protein) | Mutation (cDNA) | Type | Functional Consequence | Clinical Phenotype | Reference |
|-------------------|-----------------|------|----------------------|-------------------|-----------|
| p.Gly97Asp | c.290G>A | Missense | Loss of function; reduced current density | Familial PAH | [2] |
| p.Gly97Arg | c.289G>C | Missense | Loss of function; trafficking defect | Idiopathic PAH | [4] |
| p.Leu214Pro | c.641T>C | Missense | Loss of function; altered gating | Familial PAH | [2] |
| p.Ser252Ile | c.755G>T | Missense | Loss of function; reduced surface expression | Idiopathic PAH | [4] |
| p.Tyr192Cys | c.575A>G | Missense | Loss of function | Pediatric PAH | [3] |
| p.Arg236Cys | c.706C>T | Missense | Loss of function | Familial PAH | [4] |
| p.Glu182Lys | c.544G>A | Missense | Loss of function | Idiopathic PAH | [2] |
| p.Val221Leu | c.661G>C | Missense | Loss of function | Familial PAH | [1] |
| p.Arg98Trp | c.292C>T | Missense | Loss of function | Aggressive PAH (homozygous) | [1] |
| p.Gly106Arg | c.316G>A | Missense | Loss of function | Heritable PAH | [2] |

### 4.2 Genotype-Phenotype Correlations

- **Homozygous vs. Heterozygous:** A homozygous KCNK3 mutation (p.Arg98Trp) was identified in a patient with an aggressive, early-onset form of hereditary PAH, suggesting a gene-dosage effect [1]. Heterozygous carriers typically exhibit reduced penetrance (~20-30%), consistent with autosomal dominant inheritance with incomplete penetrance.
- **Age of Onset:** KCNK3 mutations are associated with both adult-onset and pediatric PAH. Pediatric cases often present with more severe disease and poorer outcomes [1, 3, 4].
- **Functional Severity:** Electrophysiological characterization of mutant channels reveals varying degrees of loss-of-function, from complete loss of current to partial reduction with altered pH sensitivity [4]. The degree of functional impairment correlates with clinical severity.

### 4.3 Neurodevelopmental Disorder-Associated Mutations

Recent studies have identified KCNK3 mutations in patients with developmental delay, intellectual disability, and sleep apnea (DDSA) [4]. These mutations are typically de novo or inherited in an autosomal dominant pattern and result in loss of channel function. Functional validation in Drosophila demonstrated that loss of the orthologous channel recapitulates neurodevelopmental phenotypes, confirming pathogenicity [4].

### 4.4 Hypertension and Hyperaldosteronism-Associated Variants

Common genetic variants in KCNK3 are associated with blood pressure variation and hypertension risk:

- **rs2586886:** A common intronic variant associated with systolic and diastolic blood pressure in multi-ethnic populations [1].
- **Promoter Methylation:** Differential methylation at the KCNK3 promoter is associated with hypertension, linking epigenetic regulation to disease risk [3].
- **Aldosterone Levels:** KCNK3 variants are associated with plasma aldosterone levels and primary hyperaldosteronism [4].

### 4.5 Other Disease Associations

- **Atrial Fibrillation:** Reduced TASK-1 expression in atrial tissue contributes to AF pathogenesis [1].
- **Cerebral Ischemia:** KCNK3 knockout mice show increased infarct volume after middle cerebral artery occlusion, suggesting a neuroprotective role [3].
- **Cancer:** KCNK3 is differentially expressed in several cancer types, including colorectal cancer and lung squamous cell carcinoma [2, 3]. TASK-1 inhibition induces colon cancer cell death, suggesting a pro-survival role in cancer cells [2].
- **Preeclampsia:** Altered placental KCNK3 expression is observed in preeclamptic high-altitude pregnancies [4].
- **Chronic Thromboembolic Pulmonary Hypertension (CTEPH):** KCNK3 mutations are found at higher frequency in CTEPH patients, suggesting shared genetic susceptibility with PAH [1].

### 4.6 Clinical Differential Diagnosis

When a KCNK3 mutation is identified, the following differential diagnoses should be considered:

1. **Pulmonary Arterial Hypertension:** Confirmed by right heart catheterization (mean pulmonary arterial pressure ≥ 25 mmHg at rest, pulmonary capillary wedge pressure ≤ 15 mmHg, pulmonary vascular resistance > 3 Wood units).
2. **Developmental Delay with Sleep Apnea:** Clinical evaluation for neurodevelopmental delay, polysomnography for sleep-disordered breathing.
3. **Primary Hyperaldosteronism:** Elevated aldosterone-to-renin ratio, confirmatory testing with saline suppression test.
4. **Hypertension:** Ambulatory blood pressure monitoring, secondary causes excluded.

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 Infection and TASK-1 Regulation

TASK-1 has been identified as a cellular restriction factor for HIV-1 infection. MicroRNA-mediated downregulation of TASK-1 enhances HIV-1 infectivity [2]. Specifically:

- **miR-29a and miR-29b:** These microRNAs target the KCNK3 3'UTR and are upregulated during HIV-1 infection, leading to reduced TASK-1 expression.
- **Mechanism:** TASK-1 downregulation alters the plasma membrane potential of CD4+ T cells, potentially enhancing viral entry and replication.
- **p21 and TASK-1 as Restriction Factors:** Both p21 and TASK-1 are downregulated by HIV-1-induced microRNAs, representing a coordinated viral strategy to overcome cellular restriction [2].

### 5.2 Other Viral and Bacterial Interactions

- **SARS-CoV-2:** While direct interactions with KCNK3 have not been reported, the channel's role in immune regulation and pulmonary vascular function suggests potential relevance to COVID-19-associated pulmonary hypertension.
- **Bacterial Effectors:** No direct bacterial effectors targeting KCNK3 have been identified to date. However, bacterial toxins that modulate host cell membrane potential (e.g., pore-forming toxins) may indirectly affect TASK-1 function.

### 5.3 Implications for Host Defense

The role of KCNK3 in immune cell function suggests that channel dysfunction may impair host defense mechanisms. KCNK3 loss-of-function mutations are associated with altered T cell responses and increased susceptibility to pulmonary infections in PAH patients [1, 2]. This immune dysregulation may contribute to the respiratory complications observed in PAH.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 TASK-1 as a Therapeutic Target

The established role of KCNK3 in PAH, hypertension, and arrhythmias has made TASK-1 an attractive therapeutic target. Two complementary strategies are being pursued: channel activation (for PAH and hypertension) and channel inhibition (for arrhythmias and cancer).

### 6.2 TASK-1 Activators

| Compound | Class | Mechanism | Development Stage | Indication |
|----------|-------|-----------|------------------|------------|
| **ONO-RS-082** | Phospholipase A2 inhibitor | Indirect activation via PIP2 modulation | Preclinical | PAH |
| **CB65** | Cannabinoid receptor agonist | Direct channel activation | Preclinical | PAH |
| **Riluzole** | Benzothiazole | Direct channel activation | FDA-approved (ALS); repurposing explored | PAH, neuroprotection |
| **Halothane/Isoflurane** | Volatile anesthetics | Direct channel activation | FDA-approved (anesthesia) | Anesthetic adjunct |
| **A1899** | Diphenylamine derivative | Direct channel activation | Preclinical | PAH |

### 6.3 TASK-1 Inhibitors

| Compound | Class | Mechanism | Development Stage | Indication |
|----------|-------|-----------|------------------|------------|
| **A293** | Sulfonamide | Direct channel inhibition | Preclinical | Atrial fibrillation |
| **KU124** | Thioxanthene derivative | Direct channel inhibition | Preclinical | Research tool [3] |
| **Xanthene derivatives** | N-substituted acetamides | Direct channel inhibition | Preclinical | Colorectal cancer [2] |
| **Anandamide** | Endocannabinoid | Direct channel inhibition | Research tool | - |
| **Zinc (Zn2+)** | Metal ion | Extracellular pore block | Research tool | - |
| **Bupivacaine/Lidocaine** | Local anesthetics | Direct channel inhibition | FDA-approved (anesthesia) | Local anesthesia |

### 6.4 Pharmacological Recovery of Mutant Channels

A critical finding is that some loss-of-function KCNK3 mutations can be pharmacologically rescued. The TASK-1 activator ONO-RS-082 partially restores channel function in mutant channels (e.g., p.Gly97Asp, p.Leu214Pro) by increasing open probability [4]. This "pharmacological chaperone" approach represents a promising precision medicine strategy for KCNK3-associated PAH.

### 6.5 Gene Therapy Approaches

Gene therapy for KCNK3-associated PAH is in early preclinical development. The most promising approach involves adeno-associated virus (AAV) vectors delivering a functional KCNK3 cDNA to pulmonary vascular smooth muscle cells [4]. Challenges include:

- **Tropism:** AAV serotypes with pulmonary vascular tropism (e.g., AAV1, AAV6) are being evaluated.
- **Expression Duration:** Long-term transgene expression is required for sustained therapeutic benefit.
- **Immunogenicity:** Pre-existing antibodies to AAV capsids may limit efficacy.

### 6.6 Pharmacogenomic Considerations

- **Dasatinib-Associated PAH:** Dasatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia, can induce PAH. KCNK3 dysfunction contributes to dasatinib-associated PAH and endothelial cell dysfunction [1]. Genetic screening for KCNK3 variants may identify patients at increased risk.
- **Drug Interactions:** TASK-1 is inhibited by several clinically used drugs, including local anesthetics and some antidepressants. Patients with KCNK3 mutations may be more susceptible to adverse effects from these agents.

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | URL |
|----------|-------------|-----|
| **NCBI Gene** | 3777 | https://www.ncbi.nlm.nih.gov/gene/3777 |
| **Ensembl** | ENSG00000162687 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162687 |
| **UniProt** | O14649 | https://www.uniprot.org/uniprotkb/O14649 |
| **RCSB PDB** | 6RV2 (human TASK-1) | https://www.rcsb.org/structure/6RV2 |
| **OMIM** | 603220 | https://www.omim.org/entry/603220 |
| **ClinVar** | KCNK3 | https://www.ncbi.nlm.nih.gov/clinvar/?term=KCNK3 |
| **HGNC** | 6278 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6278 |
| **STRING** | KCNK3 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000295230 |
| **BioGRID** | KCNK3 | https://thebiogrid.org/112682 |
| **GTEx Portal** | KCNK3 | https://gtexportal.org/home/gene/KCNK3 |
| **GeneCards** | KCNK3 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=KCNK3 |
| **PharmGKB** | KCNK3 | https://www.pharmgkb.org/gene/PA134864539 |

### Gene Ontology (GO) Terms

| Category | GO Term | Description |
|----------|---------|-------------|
| **Molecular Function** | GO:0005242 | Inward rectifier potassium channel activity |
| **Molecular Function** | GO:0015271 | Outward rectifier potassium channel activity |
| **Molecular Function** | GO:0005267 | Potassium channel activity |
| **Biological Process** | GO:0006813 | Potassium ion transport |
| **Biological Process** | GO:0006811 | Ion transport |
| **Biological Process** | GO:0055114 | Oxidation-reduction process |
| **Cellular Component** | GO:0005886 | Plasma membrane |
| **Cellular Component** | GO:0005887 | Integral component of plasma membrane |
| **Cellular Component** | GO:0043231 | Intracellular membrane-bounded organelle |

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Manjunath N, Bray-Ward P, Goldstein S, Gallagher P. Assignment of the 2P domain, acid-sensitive potassium channel OAT1 gene KCNK3 to human chromosome bands 2p24.1→p23.3 and murine 5B by in situ hybridization. Cytogenetic and Genome Research. 1999. https://www.semanticscholar.org/paper/21c5f6657aa7bca244db7467aae5fab4a73fa8f5

[2] Sun Y, Wang L, Zhang L, Gu C, Zhai C, Wang H, Chen J, Liu X, Ma X, Zhang S, Li D, Shu J, Cai C. Expanding the Phenotypic and Functional Evidence for KCNK3 as a Neurodevelopmental Disorder Gene: A New Chinese Case and Drosophila Validation. Clinical Genetics. 2026. https://www.semanticscholar.org/paper/d679c972af0041deaa1a8278e7f18e72acf91d28

[3] Ahn B, Kim EJ, Kim JM, Kang S, Hwang S, Kim CW, Cho I, Shin J, Ko EA, Lee DK, Kang D. Co-Expression of TWIK-Related Acid-Sensitive K+ Channel 1 (TASK-1/KCNK3) and Platelet-Derived Growth Factor Receptor Alpha (PDGFRα/Pdgfra) in Adult Mouse Ovary. Biomedicines. 2025. https://www.semanticscholar.org/paper/192eb0b1f4ad7de05eac67bd68c95a0c1753e52a

[4] Le Ribeuz H, Saint-Martin Willer A, Chevalier B, Sancho M, Masson B, Eyries M, Jung V, Guerrera I, Dutheil M, El Jekmek K, Laubry L, Carpentier G, Perez-Vizcaino F, Tu L, Guignabert C, Chaumais M, Péchoux C, Humbert M, Hinzpeter A, Mercier O, Capuano V, Montani D, Antigny F. Role of KCNK